US Bancorp’s Terns Pharmaceuticals TERN Stock Holding History

US Bancorp’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,190	Closed	-$274K	–	4337
2026 Q1	$274K	Buy	5,190 +583	+13%	+$23.9K	﹤0.01%	1843
2025 Q4	$186K	Buy	4,607 +4,066	+752%	+$94K	﹤0.01%	2065
2025 Q3	$4.06K	Sell	541 -1,130	-68%	-$7.22K	﹤0.01%	3596
2025 Q2	$6.23K	Sell	1,671 -779	-32%	-$2.43K	﹤0.01%	3569
2025 Q1	$6.76K	Buy	+2,450	New	+$10K	﹤0.01%	3564
2024 Q3	–	Sell	-600	Closed	-$4.09K	–	4180
2024 Q2	$4.09K	Sell	600 -95	-14%	-$575	﹤0.01%	3576
2024 Q1	$4.56K	Buy	695 +309	+80%	+$2.02K	﹤0.01%	3547
2023 Q4	$2.5K	Buy	386 +89	+30%	+$471	﹤0.01%	3664
2023 Q3	$1.49K	Buy	+297	New	+$1.88K	﹤0.01%	3708

Other funds holding TERN

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

US Bancorp's TERN Position: Q2 2026 in Review

US Bancorp sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 5,190 shares — an estimated $274K sold.

US Bancorp first reported a position in TERN in Q3 2023 and held it in 9 quarters. The position peaked at $274K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

US Bancorp reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
US Bancorp sold 5,190 Terns Pharmaceuticals shares in Q2 2026, an estimated $274K.
US Bancorp first reported a position in Terns Pharmaceuticals in Q3 2023 and held it in 9 quarters.
US Bancorp's Terns Pharmaceuticals position peaked at $274K in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.